All

SumUp Hires Former Mangopay CGO Pierre Lion to Expand Its Enterprise Offering
23 May 2025

SumUp Hires Former Mangopay CGO Pierre Lion to Expand Its Enterprise Offering

Global fintech, SumUp is pleased to announce the hiring of Pierre Lion as Global Director of Enterprise Sales, who will be responsible for the growth of the fintech’s...

Read more
Animab Secures EUR 10 Million in Series B Financing to Launch Nanoprotec® in Europe and Expand Pipeline
23 April 2025

Animab Secures EUR 10 Million in Series B Financing to Launch Nanoprotec® in Europe and Expand Pipeline

•All current investors participated in the round led by AIF,PMV and QBIC III, alongside new investor Anacura.
•Funds will support EU commercialization of...

Read more
Citryll demonstrates a broader therapeutic potential for cit-013 in the treatment of inflammatory disorders
24 February 2025

Citryll demonstrates a broader therapeutic potential for cit-013 in the treatment of inflammatory disorders

Breakthrough study published in Frontiers in Immunology demonstrates CIT-013’s effectiveness against additional types of extracellular traps, expanding potential therapeutic...

Read the press release
Ekstere raises €2,4 million to make cycling truly sustainable !
12 February 2025

Ekstere raises €2,4 million to make cycling truly sustainable !

Entry of Ekstere into the Sport and Performance Capital funds of Seventure Partners.
Structuring the second-hand bike market through listing.
Make sustainable...

Read the press release
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
30 January 2025

Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors

Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa...

Read more
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
8 January 2025

MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease

The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of MaaT013 as...

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
10 December 2024

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

These findings underscore MaaT013’s potential as a transformative therapy for aGvHD, a condition with poor survival rates and limited treatment options. The high response...

Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders
9 December 2024

Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders

Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), announces...

Read more
MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease
5 December 2024

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more